Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous anti-IL-1RAP CAR T cells CCTx-001

A preparation of autologous CD4+ and CD8+ T lymphocytes that have been transduced to express a chimeric antigen receptor (CAR) consisting of an anti-interleukin-1 receptor accessory protein (IL-1RAP; IL-1 receptor 3; IL-1R3) single chain variable fragment (scFv) coupled to the hinge domain of human immunoglobulin G1 (IgG1), the co-stimulatory signaling domain CD28, the signaling domain of 4-1BB (CD137), and the zeta chain of the T-cell receptor (TCR)/CD3 complex (CD3zeta), with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-IL-1RAP CAR T cells CCTx-001 specifically recognize and kill IL-1RAP-expressing tumor cells. IL-1RAP, a transmembrane glycoprotein, is highly expressed on leukemic cells but not on healthy hematopoietic stem and progenitor cells (HSPCs); its expression has been correlated with poor prognosis.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous anti-IL-1RAP CAR-T cells CCTx-001
Code name:CCTx 001
CCTx-001
CCTx001
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search